TABLE 5.
Antiarrhythmic drug recommendations for rhythm control since 2014. a
| Comorbidities | No structural heart disease | Coronary artery disease | Heart failure |
|---|---|---|---|
| Flecainide (class IC) b , c | First-line | — | — |
| Propafenone (class IC) b , c | First-line | — | — |
| Sotalol (class III) b , d | First-line | First-line | — |
| Dronedarone (class III) | First-line | First-line | — |
| Dofetilide (class III) b , d | First-line | First-line | First-line |
| Amiodarone (class III) | Second-line | Second-line | First-line |
a
Based on the 2014 AHA/ACC/HRS guideline for atrial fibrillation management (January et al., 2014).
b
Avoid in severe left ventricular hypertrophy (wall thickness > 1.5 cm).
c
To combine with atrioventricular nodal blocking drugs.
d
Caution in high risk for torsades de pointes.